» Articles » PMID: 35664056

Continuous Centrifugal Microfluidics (CCM) Isolates Heterogeneous Circulating Tumor Cells Via Full Automation

Abstract

Understanding cancer heterogeneity is essential to finding diverse genetic mutations in metastatic cancers. Thus, it is critical to isolate all types of CTCs to identify accurate cancer information from patients. Moreover, full automation robustly capturing the full spectrum of CTCs is an urgent need for CTC diagnosis to be routine clinical practice. Here we report the full capture of heterogeneous CTC populations using fully automated, negative depletion-based continuous centrifugal microfluidics (CCM). The CCM system demonstrated high performance (recovery rates exceeding 90% and WBC depletion rate of 99.9%) across a wide range of phenotypes (EpCAM(+), EpCAM(-), small-, large-sized, and cluster) and cancers (lung, breast, and bladder). Applied in 30 lung adenocarcinoma patients harboring epidermal growth factor receptor (EGFR) mutations, the system isolated diverse phenotypes of CTCs in marker expression and size, implying the importance of unbiased isolation. Genetic analyses of intra-patient samples comparing cell-free DNA with CCM-isolated CTCs yielded perfect concordance, and CTC enumeration using our technique was correlated with clinical progression as well as response to EGFR inhibitors. Our system also introduces technical advances which assure rapid, reliable, and reproducible results, thus enabling a more comprehensive application of robust CTC analysis in clinical practice.

Citing Articles

Lessons (to be) learned from liquid biopsies: assessment of circulating cells and cell-free DNA in cancer and pregnancy-acquired microchimerism.

Bergmann L, Afflerbach A, Yuan T, Pantel K, Smit D Semin Immunopathol. 2025; 47(1):14.

PMID: 39893314 PMC: 11787191. DOI: 10.1007/s00281-025-01042-z.


Enhanced detection of circulating tumor cells using a MUC1 promoter-driven recombinant adenovirus.

Wang C, Gu H, Cai J, Zhu C, Zheng Q, Xu H Front Oncol. 2025; 14:1506968.

PMID: 39886667 PMC: 11779711. DOI: 10.3389/fonc.2024.1506968.


Minimal residual disease as a target for liquid biopsy in patients with solid tumours.

Pantel K, Alix-Panabieres C Nat Rev Clin Oncol. 2024; 22(1):65-77.

PMID: 39609625 DOI: 10.1038/s41571-024-00967-y.


Circulating tumor cells: from new biological insights to clinical practice.

Gu X, Wei S, Lv X Signal Transduct Target Ther. 2024; 9(1):226.

PMID: 39218931 PMC: 11366768. DOI: 10.1038/s41392-024-01938-6.


The prognostic significance of circulating tumor cell enumeration and HER2 expression by a novel automated microfluidic system in metastatic breast cancer.

Wang L, Hong R, Shi S, Wang S, Chen Y, Han C BMC Cancer. 2024; 24(1):1067.

PMID: 39210288 PMC: 11360297. DOI: 10.1186/s12885-024-12818-1.


References
1.
Abdulla A, Zhang T, Li S, Guo W, Warden A, Xin Y . Integrated microfluidic single-cell immunoblotting chip enables high-throughput isolation, enrichment and direct protein analysis of circulating tumor cells. Microsyst Nanoeng. 2022; 8:13. PMC: 8807661. DOI: 10.1038/s41378-021-00342-2. View

2.
Kong B, Lee C, Cho Y . Protocol for the assessment of human T cell activation by real-time metabolic flux analysis. STAR Protoc. 2022; 3(1):101084. PMC: 8761778. DOI: 10.1016/j.xpro.2021.101084. View

3.
Kim J, Cho H, Kim J, Park J, Han K . A disposable smart microfluidic platform integrated with on-chip flow sensors. Biosens Bioelectron. 2020; 176:112897. DOI: 10.1016/j.bios.2020.112897. View

4.
Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, Phelps R . Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry. 2002; 49(4):150-8. DOI: 10.1002/cyto.10161. View

5.
Rushton A, Nteliopoulos G, Shaw J, Coombes R . A Review of Circulating Tumour Cell Enrichment Technologies. Cancers (Basel). 2021; 13(5). PMC: 7956528. DOI: 10.3390/cancers13050970. View